Find a Provider

Bruce J. Giantonio, MD

Bruce J. Giantonio, MD Physician

Executive Officer, The Eastern Cooperative Oncology Group
Associate Professor of Medicine at the Hospital of the University of Pennsylvania and the Presbyterian Medical Center of Philadelphia

Dr. Giantonio is a Penn Medicine employed physician.

Clinical Specialties


  • Medicine
    • Medical Oncology

Programs & Services:

  • Cancer
    • Anal Cancer
    • Colon Cancer
    • Esophageal Cancer
    • Gastrointestinal Carcinoid Tumor
    • Liver Cancer
    • Pancreatic Cancer
    • Rectal Cancer
    • Small Intestine Cancer
    • Stomach (Gastric) Cancer
  • LGBT Health

Board Certification:

  • Internal Medicine, 1991
  • Medical Oncology, 1993

Conditions & Treatments:

  • Anal Cancer
  • Bile Duct Cancer
  • Colon Cancer
  • Esophageal Cancer
  • Gallbladder Cancer
  • Gastrointestinal Carcinoid Tumor
  • Gastrointestinal Stromal Tumors (GIST)
  • Liver Cancer
  • Liver Tumors
  • Neuroendocrine Tumors
  • oral cavity cancer
  • Pancreatic Cancer
  • parathyroid tumor
  • Rectal Cancer
  • Sinus Cancer
  • Small Intestine Cancer
  • Stomach (Gastric) Cancer
  • Throat Cancer
  • Thyroid Cancer

Clinical Interests

Treatment of all gastrointestinal malignancies

Practice Locations and Appointments

  • Gastrointestinal Oncology

    Abramson Cancer Center Perelman Center for Advanced Medicine, West Pavilion, 4th Floor 3400 Civic Center Boulevard Philadelphia, PA 19104 800-789-PENN (7366)

    A facility of the Hospital of the University of Pennsylvania

Insurance Accepted

  • Aetna US Healthcare
  • Cigna
  • Cigna HealthSpring
  • Devon Health Services (Americare)
  • Gateway Health Plan
  • Geisinger Health Plan
  • HealthAmerica / HealthAssurance, a Coventry Plan
  • HealthPartners
  • HealthSmart
  • Highmark Blue Shield
  • Horizon Blue Cross Blue Shield of New Jersey
  • Humana / Choicecare
  • Independence Blue Cross (Keystone East)
  • Intergroup
  • Keystone First
  • Multiplan
  • NJ Medicaid
  • NJ Qualcare
  • Oxford Health Plan
  • PA Medicaid
  • PA Medicare
  • Preferred Care
  • Rail Road Medicare / Palmetto GBA
  • Tricare
  • United Healthcare
  • UnitedHealthcare Community Plan
  • US Family Health Plan

Education and Training

Medical School: Georgetown University School of Medicine
Residency: Medical Center Hospital of Vermont
Fellowship: Fox Chase Cancer Center


American Association for the Advancement of Science, National American College of Physicians, National American Society of Clinical Oncology, National ECOG-ACRIN Cancer Research Group, National PrECOG, National Working Group for the NCI Concise Informed Consent Template Project, The National Cancer Institute, National


Dr. Giantonio is a Penn Medicine employed physician.

Hospital Privileges:

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.


Research Interests:

Clinical Investigation of targeted agents in gastrointestinal malignancies

Selected Publications:

Dolinsky, C.M., Mahmoud, N.N., Sun, W., Whittington, R.W., Solin, L.J., Haller, D.G., Giantonio, B.J., O’Dwyer, P.J., Rosato, E.F., Fry, R.D., Metz, J.M.: Effect of time interval between surgery and preoperative chemoradiotherapy with 5-Fluorouracil or 5-fluorouracil and oxaliplatin on outcomes in rectal cancer. J Surg Oncol 96 (3): 207-212,2007.

Giantonio, B., Catalano, P.J., Meropol, N.J., O’Dwyer, P.J., Michell, E. P., Alberts, S.R., Schwartz, M.A., Benson, A.B.: Bevacizumab in Combination with Oxaliplatin, Fluorouracil and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 25 (12): 1539-1544,2007.

Giantonio, B.J.: Bevacizumab in the treatment of metastatic colorectal cancer (mCRC) in second- and third-line settings. Seminars in Oncology 33 (5 Suppl 10): S15-8,2006.

Giantonio, B., Levy, D., O’Dwyer, P., Meropol, N., Catalano, P., Benson, A. 3rd: A Phase II study of high-dose bevacizumab in combination with irinotecan, 5-fluorouracil, leucovorin, as initial therapy for advanced colorectal cancer: results from the Eastern Cooperative Group Study E2200 Ann Oncol 17 (9): 1399-1403,2006.

Veronese, M.L., Sun, W., Giantonio, B., Berlin, J., Shults, J., Davis, L., Haller, D.G., O'Dwyer, P.J.: A phase II trial of gefitinib with 5-fluorouracil, leucovorin, and irinotecan in patients with colorectal cancer. British Journal of Cancer 92 (10): 1846-1849,2005.

Bilenker, J.H., Flaherty, K.T., Rosen, M., Davis, L., Gallagher, M., Stevenson, J.P. Sun, W., Vaughn, D., Giantonio, B., Zimmer, R., Schnall, M., O'Dwyer, P.J.: Phase I trial of combretastatin a-4 phosphate with carboplatin Clin Cancer Research 11 (4): 1527-1533,2005.

Bilenker, J.H., Stevenson, J.P., Flaherty K.T., Algazy, K., McLaughlin, K., Haller, D.G., Giantonio, B.J., Koehler, M., Garcia-Vargas, J.E., O’Dwyer, P.J.: Phase I trial of the antifolate ZD9331 in combination with cisplatin in patients with refractory solid malignancies. Cancer Chemother Pharmacol 53 (4): 357-360,2004.

Giantonio, B.J., Derry, C., McAleer, C., McPhillips, J.J., O’Dwyer, P.J: Phase I and pharmacokinetic study of the cytotoxic ether lipid ilmofosine administered by weekly 2 hour infusion in patients with advanced solid tumors Clin Cancer Research 10 : 1282-1288,2004.

Sun, W., Whittington, R., Gallagher, M., O'Dwyer, P., Giantonio, B., Metz, J., Haller, D.: Concurrent RT with 5-FU/epirubicin and cisplatin or irinotecan for locally advanced upper GI adenocarcinoma. Oncology. 18 ((14 Suppl 14)): 39-42,2004.

Veronese, M.L., Stevenson, J.P., Sun, W., Redlinger, M., Algazy, K., Giantonio, B., Hahn, S., Vaughn, D., Thorn, C., Whitehead, A.S., Haller, D.G., O’Dwyer, P.J.: Phase I trial of UFT/Leucovorin and irinotecan in patients with advanced cancer. Eur J Cancer 40 : 508-514,2004.

Academic Contact Info

16 Penn Tower
3400 Spruce Street

Philadelphia, PA 19104
Phone: (215) 662-6318
Fax: (215) 349-5326
Patient appointments: 800-789-PENN (7366)

Related Links